Alzheimer’s disease is a devastating and progressive neurodegenerative disease. Current therapeutics offer temporary symptomatic relief, and while many companies have tried to develop drugs that slow the pace of the disease or even reverse it, there has been no success in new drug approval since 2003. Athira Pharma, Inc.’s objective is to change this reality. From small beginnings a few years ago, the company has advanced its lead therapeutic, NDX-1017, into clinical trials in Alzheimer’s disease. (Athira was previously known as M3 Biotechnology. The company changed its name in April 2019.) Athira’s mission is to restore lives by advancing bold therapies, thoughtfully and urgently.
Building a company
Athira grew from research that emerged in Joseph Harding’s laboratory at Washington State University, USA. Harding approached Jordan-born Leen Kawas, then a postdoctoral researcher and now Athira’s president and CEO, with the suggestion that she work with him to commercialize the team’s neurodegen-erative disease findings. “We saw that novel compounds we were working on had an impact in both Alzheimer’s disease and Parkinson’s disease models, and we licensed the technology from the university. Work continued at the company on optimizing the molecules and lead identification; we selected our lead compound in 2016,” said Kawas.
Athira now employs 15 people within its core team, in drug discovery and in clinical development, which is surrounded by a larger network of consultants, advisors and service providers. “We are working in the same arena as some very large pharmaceutical companies, but we see our lean operations as an advantage. We are able to be much more flexible and we have succeeded in getting to the clinic efficiently and effectively,” said Kawas.
Meeting the challenge of neurodegeneration
While there are many companies with a focus on neurodegenerative diseases and a number of symptomatic drugs on the market, there remains a great need for effective solutions. Athira’s drug candidates employ a completely different mechanism of action to other drugs currently in development, according to Kawas; they act by activating key brain neurotrophic receptors (Fig. 1).
Kawas and her team believe that their approach, which looks to restore lost or build new connections in the brain, could halt or even reverse the progress of different neurodegenerative diseases. But the indications that the company has chosen to investigate, particularly Alzheimer’s disease, are so far scattered with drugs that have not succeeded. Many companies have focused on β-amyloid and the amyloid hypothesis to develop drugs to try to beat Alzheimer’s disease.
“We believe that using β-amyloid as the target is where companies have failed. The β-amyloid levels are stable at diagnosis, so it may not be the main mechanism for the worsening of the disease. We need to think outside of the box,” said Kawas. “Despite the failures that we have seen in Alzheimer’s disease, there has been a lot achieved in the understanding of the pathology and presentation of the disorder, and there is also a lot of support from the regulatory authorities.” Athira’s decision to enter into the neurodegeneration market was based on science and
business, but also on personal associations and experiences. “To work in an area like neurodegenerative disease you need the science and business drivers, but you also need the personal links—which exist for me and members of my team—to give it energy and make it a passion,” said Kawas.
Improving the approach to clinical trials
Another area in which Athira is thinking outside of the box is in its design and operation of clinical trials. “Preclinical trials don’t always translate well into clinical trials, and so we have chosen our endpoints carefully,” said Kawas. To ensure that early research progresses smoothly into later-stage development, researchers at Athira are looking at a range of bio-markers, including electroencephalogram (EEG) and functional and structural magnetic resonance imaging biomarkers, as well as plasma and cerebrospinal fluid markers. These can be used in animal studies, but have also been validated in clinical trials.
Another significant barrier in clinical trial development is the creation of studies that address the inherent challenges of testing in this patient population. Athira is advancing a patient-centric approach to clinical trial design in the hopes of improving outcomes for everyone. “Neurodegenerative diseases, including Alzheimer’s disease, are challenging to study in controlled trials, as these need to be large and long. There tend to be high levels of patient drop-out and recruitment can be difficult, and as a result the data quality can be low,” said Kawas. “We have learned from the failed trials. We work closely with patients and caregivers and build patient-centric trials based on their feedback representing what they actually want and what they are willing to do.”
This patient centricity and inclusion of patient voice should improve the clinical trial experience for patients and caregivers. This will increase recruitment rates and retention which will ultimately improve the quality of the trials. “We are heeding domestic and international regulatory guidelines and positioning our program for acceleration,” said Kawas.
Moving Athira’s approach into the clinic
In October 2017, Athira began testing NDX-1017, its lead small molecule, in patients with Alzheimer’s disease or dementia, following phase 1a safety and tolerability testing in healthy younger people and phase 1b testing in healthy older people. “We chose NDX-1017 as our lead molecule based on its high potency, favorable safety profile and its ease of formulation and manufacturing,” said Kawas.
In preclinical studies, NDX-1017 promoted neurore-generation in brain cells and synapses and improved cognitive function, with therapeutic potential in a range of neurodegenerative diseases. It also showed a good safety and tolerability profile. Following its biomarker-based approach, the Athira team included an EEG biomarker in both preclinical and clinical trials. “When we moved NDX-1017 into the clinic, we saw that the safety and pharmacokinetics translated well from the preclinical studies,” said Kawas. “ Next year we plan to take NDX-1017 into a larger proof-of-concept study with cognitive endpoints and with biomarkers that relate to degeneration, regeneration, inflammation, and to tau.”
NDX-1017 may also have potential for use in combination with symptomatic Alzheimer’s disease drugs, and even with drugs that have previously failed, as the different mechanisms of action of these drugs may work together.
“When looking at monotherapies and combination therapies for Alzheimer’s disease, we believe that it will depend on the stage of the disease and on the mechanism behind the different components. Monotherapies that are preventive or neuroprotective may be better for earlier stages of the disease, with combinations that both clear the protein load and promote regeneration at a later stage,” said Kawas. “We are looking at combinations in preclinical trials.”
The promise of new approaches like Athira’s has begun to attract the attention of those within the Alzheimer’s community. The company is excited to continue building and growing those connections as trials advance. “There is a tremendous and growing need for new, innovative approaches that may one day change the course of Alzheimer’s disease,” said Howard M. Fillit, founding executive director and CSO at the Alzheimer’s Drug Discovery Foundation (ADDF), a philanthropic organization focused on finding drugs to prevent, treat and cure Alzheimer’s. “The aim of the ADDF is to advance and accelerate drug discovery and development by supporting exciting, novel ideas, such as the work of Athira Pharma, Inc.”
Developing a pipeline
Maintaining a broad development pipeline is important to Kawas, as she sees that having a number of assets provides both flexibility and increases the chance of success by having “multiple shots on goal” (Fig. 2). Athira is evaluating the use of NDX-1017 in additional therapeutic indications, with the planning of a phase 2 trial in Parkinson’s disease in the near future. Because of its neuroregenerative mechanism of action, it could also have potential for other neurodegenerative diseases. “We also have additional compounds in our discovery pipeline for Alzheimer’s disease, amyotrophic lateral sclerosis and Parkinson’s disease. We will also look at other mechanisms of action. Most of our pipeline will come from in-house discovery, but we may also in-license potential candidates,” said Kawas.
Athira’s efforts to date have been supported through private investment and nondilutive grant support. Since its founding, Athira has received nearly $20 million from two oversubscribed rounds of equity financing. Key supporters include the Alzheimer’s Drug Discovery Foundation, Dolby Family Ventures, W Fund, WRF Capital and many private investors. “As we expand our discovery pipeline, and start multiple clinical programs, we plan to scale up our team to meet our needs. We will fund this expansion, to around twice the current size, and our further clinical trials, using our third round of funding.”
Building the future
In the long term, Athira hopes to build a strong late-stage development infrastructure and looks toward commercialization. In the short and midterm, however, the company plans to continue with its strengths in discovery and early clinical-stage development, while building strategic partnerships for marketing NDX-1017 and its other initial targets and compounds. “We would like to grow to the point that we can market our own products. Until then, collaborations with commercialization partners could increase our chances of success on the market,” said Kawas. “Our primary goal remains that of impacting the course of neurodegenerative diseases. We will continue to progress our science and programs as efficiently and rapidly as possible toward this end goal.”